CY2531B1 - Guanine derivative - Google Patents

Guanine derivative

Info

Publication number
CY2531B1
CY2531B1 CY0500061A CY0500061A CY2531B1 CY 2531 B1 CY2531 B1 CY 2531B1 CY 0500061 A CY0500061 A CY 0500061A CY 0500061 A CY0500061 A CY 0500061A CY 2531 B1 CY2531 B1 CY 2531B1
Authority
CY
Cyprus
Prior art keywords
guanine derivative
guanine
derivative
Prior art date
Application number
CY0500061A
Other languages
English (en)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnike
William Bayne Grubb Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2531(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of CY2531B1 publication Critical patent/CY2531B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CY0500061A 1995-01-20 2005-11-16 Guanine derivative CY2531B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
CY2531B1 true CY2531B1 (en) 2006-04-12

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500061A CY2531B1 (en) 1995-01-20 2005-11-16 Guanine derivative

Country Status (40)

Country Link
US (1) US6107302A (OSRAM)
EP (1) EP0804436B1 (OSRAM)
JP (1) JP3176633B2 (OSRAM)
KR (1) KR100376074B1 (OSRAM)
CN (1) CN1049893C (OSRAM)
AP (1) AP662A (OSRAM)
AR (1) AR002270A1 (OSRAM)
AT (1) ATE302777T1 (OSRAM)
AU (1) AU702794B2 (OSRAM)
BG (1) BG63393B1 (OSRAM)
BR (1) BR9606768A (OSRAM)
CA (1) CA2210799C (OSRAM)
CY (1) CY2531B1 (OSRAM)
CZ (1) CZ297065B6 (OSRAM)
DE (1) DE69635106T2 (OSRAM)
DK (1) DK0804436T3 (OSRAM)
EA (1) EA000364B1 (OSRAM)
EE (1) EE03528B1 (OSRAM)
ES (1) ES2248806T3 (OSRAM)
FI (1) FI973063L (OSRAM)
GB (1) GB9501178D0 (OSRAM)
GE (1) GEP20001940B (OSRAM)
HR (1) HRP960024B1 (OSRAM)
HU (1) HU222993B1 (OSRAM)
IL (1) IL116831A (OSRAM)
IN (1) IN182468B (OSRAM)
IS (1) IS2268B (OSRAM)
NO (1) NO315558B1 (OSRAM)
NZ (1) NZ298851A (OSRAM)
OA (1) OA10499A (OSRAM)
PL (1) PL182175B1 (OSRAM)
RO (1) RO118693B1 (OSRAM)
RS (1) RS49518B (OSRAM)
SI (1) SI0804436T1 (OSRAM)
SK (1) SK285329B6 (OSRAM)
TR (1) TR199700656T1 (OSRAM)
UA (1) UA46001C2 (OSRAM)
UY (1) UY25779A1 (OSRAM)
WO (1) WO1996022291A1 (OSRAM)
ZA (1) ZA96449B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
PT874631E (pt) * 1996-01-19 2004-04-30 Glaxo Group Ltd Utilizacao de valaciclovir para a manufactura de um medicamento para o tratamento de herpes genital por aplicacao diaria unica
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 ｚ-발라사이클로비르 결정
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
HUP0500753A3 (en) * 2001-09-07 2006-05-29 Teva Pharma Crystalline forms of valacyclovir hydrochloride
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MY164581A (en) * 2008-08-15 2018-01-15 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
PH12014500137A1 (en) 2011-07-15 2017-08-18 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
AP662A (en) 1998-08-19
YU3396A (sh) 1998-12-23
FI973063A0 (fi) 1997-07-18
KR19980701525A (ko) 1998-05-15
SK96597A3 (en) 1998-02-04
RS49518B (sr) 2006-10-27
WO1996022291A1 (en) 1996-07-25
NO315558B1 (no) 2003-09-22
NO973326L (no) 1997-09-16
IS2268B (is) 2007-07-15
EA199700124A1 (ru) 1997-12-30
JPH11503718A (ja) 1999-03-30
GB9501178D0 (en) 1995-03-08
CA2210799C (en) 2008-06-10
EE03528B1 (et) 2001-10-15
IL116831A (en) 1998-10-30
JP3176633B2 (ja) 2001-06-18
EP0804436B1 (en) 2005-08-24
EE9700175A (et) 1998-02-16
MX9705462A (es) 1997-10-31
ATE302777T1 (de) 2005-09-15
CZ229497A3 (en) 1997-12-17
BR9606768A (pt) 1997-12-30
AR002270A1 (es) 1998-03-11
AP9701058A0 (en) 1997-10-31
PL321326A1 (en) 1997-12-08
ES2248806T3 (es) 2006-03-16
IS4527A (is) 1997-07-15
HRP960024B1 (en) 2005-08-31
SK285329B6 (sk) 2006-11-03
EA000364B1 (ru) 1999-06-24
PL182175B1 (pl) 2001-11-30
HUP9801836A2 (hu) 1999-05-28
SI0804436T1 (sl) 2006-02-28
RO118693B1 (ro) 2003-09-30
KR100376074B1 (ko) 2003-06-02
DK0804436T3 (da) 2005-12-27
HU222993B1 (hu) 2004-01-28
GEP20001940B (en) 2000-02-05
CZ297065B6 (cs) 2006-08-16
BG101833A (bg) 1998-04-30
TR199700656T1 (xx) 1998-03-21
US6107302A (en) 2000-08-22
NZ298851A (en) 1999-01-28
NO973326D0 (no) 1997-07-18
EP0804436A1 (en) 1997-11-05
CN1179159A (zh) 1998-04-15
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
UA46001C2 (uk) 2002-05-15
FI973063A7 (fi) 1997-09-18
CA2210799A1 (en) 1996-07-25
FI973063L (fi) 1997-09-18
HRP960024A2 (en) 1997-10-31
OA10499A (en) 2002-04-10
UY25779A1 (es) 2000-08-21
DE69635106T2 (de) 2006-06-08
AU702794B2 (en) 1999-03-04
HUP9801836A3 (en) 1999-06-28
IN182468B (OSRAM) 1999-04-17
DE69635106D1 (de) 2005-09-29
IL116831A0 (en) 1996-05-14
AU4453996A (en) 1996-08-07
ZA96449B (en) 1996-08-07

Similar Documents

Publication Publication Date Title
HRP960024B1 (en) Guanine derivative
GB9508565D0 (en) Quiazoline derivative
NZ305444A (en) 4-anilino-7-alkoxy-quinazoline derivatives
IL152383A0 (en) 5-amino-3-cyano-4-ethylsulfinyl-1- phenyl-pyrazole derivatives
IL135376A0 (en) Hydroxyalkyl-phenyl derivatives
GB2306473A8 (en) Glucoxide derivatives
ZA96228B (en) Indolepiperidine derivatives
HU9600876D0 (en) Benzonitril- and -fluoride derivatives
SG64953A1 (en) Purin-6-one derivatives
HUP9600107A2 (en) 9-substituted-2-(2-n-alkoxy-phenyl)-purin-6-one derivatives
NZ332395A (en) Benzonthiazole derivatives
SI0758644T1 (en) Sulfonyl- or sulfinyl-benzoyl-guanidine derivatives
HUP9900672A3 (en) Pyrroloazepine derivatives
SG60005A1 (en) 1-Fluorocyclohexene-difluorophenyl derivatives
IL123621A0 (en) Diarylalkenylamine derivatives
GR3035577T3 (en) Benzisothiazolyl-substituted aminomethylchroman derivatives
ZA964470B (en) Cycloalkane-benzylidene derivatives
IL117858A0 (en) 4-Indolypiperazinyl derivatives
GR3036572T3 (en) 4-amino-benzoylguanidine derivatives
HU9602324D0 (en) Piperidinyl-methyl-oxazolidinon derivatives
EP0754668A3 (de) Fluorbenzylether-Derivate
ZA967204B (en) Alkenyl-benzoylguanidine derivatives
PL324892A1 (en) Aza-antracyclinone derivatives
ZA96701B (en) 4-Mercaptobenzoylgaunidine derivatives
GB2308593A (en) Imidazopyridedine derivatives